All In Biotech

Drug Trial Radar · NCT05133804

Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD

The Relation Between Attentional, Sensory and Emotional Dysregulation in Adults With Posttraumatic Stress Disorder: a Double-blind, Placebo-controlled Randomized Controlled Trial of the Combined Treatment With Reboxetine and Methylphenidate

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

53

Planned (sponsor's estimate)

Start

Jun 1, 2022

Primary completion

Oct 1, 2026

Study completion Dec 1, 2026

Sponsor

Lead sponsor
University of HaifaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Up-to-date, no studies have examined the attentional, sensory and emotional processing (difficulties) among patients diagnosed with Posttraumatic Stress Disorder (PTSD). In addition, the efficiency of drug treatments that focus on the noradrenergic and dopaminergic, and thus influence attention processing and PTSD symptoms through these pathways, have only briefly been investigated. There is well-established and long-standing evidence for the involvement of dopamine and noradrenaline in attentional function. This previously led to an investigation by the investigator's research lab in which the investigators hypothesized the involvement of an attentional disorder would influence PTSD symptoms in a rat model. Based on these results, the current study aims to characterize attentional deficits in patients with PTSD, as well as the correlation between attention, emotional regulation and sensory processing. The investigators do this partially by conducting a case-control study and through a subsequent double-blind RCT (with only the cases). The patients will be either treated with reboxetine + methylphenidate or placebo.

Conditions

  • Posttraumatic Stress Disorder

Interventions

  • MethylphenidateDrug

    Ritalin 10mg

  • ReboxetineDrug

    Reboxetine 4mg

  • PlaceboDrug

    Placebo matched to Reboxetine

  • PlaceboDrug

    Placebo matched to Ritalin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Clinician-Administered Posttraumatic Stress Disorder Scale for the Diagnostic and Statistical Manual (DSM)-5 (CAPS-5) between baseline score (before treatment) and score on day 26 (after treatment)Time frame: Day 1 and day 26

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Emek Medical Center

    Afula, Israel · Recruiting

  • University of Haifa

    Haifa, Israel · Recruiting

  • Lev HaSharon Mental Health Center

    Netanya, Israel · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.